

# Specialty Medication Administration

## Site of Care Policy



Effective June 1, 2017, HAP will no longer pay facility fee schedules for the medications listed in the enclosed Specialty Medication Administration - Site of Care Policy. This policy applies to the following specialty medications\* as of June 2017:

- J0129, Abatacept (Orencia®)
- J1602, Golimumab (Simponi Aria®)
- J1745, Infliximab (Remicade®)
- Q5102, Infliximab biosimilar (Inflectra®)
- J2505, Pegfilgrastim (Neulasta®)
- J3262, Tocilizumab (Actemra®)

\*NOTE: Specialty Medications that can be safely self-administered or safely administered in a non-outpatient hospital setting majority of the time will be continuously evaluated for addition to this policy.

Alternative sites of care such as non-hospital outpatient infusions, physician offices, ambulatory infusions or home infusions are well accepted places of service for medication infusion therapy. Initial medication infusion or re-initiation after more than six months following discontinuation of therapy will be covered with a facility fee schedule. Please see the policy for circumstances when a facility fee will be allowed for specialty medications administered in a hospital outpatient facility and a complete listing of other criteria that qualify for facility fee schedule billing.

For drugs that can be self-administered, an outpatient pharmacy can be used for provision of drug therapy. If a patient cannot self-administer the injection, HAP will provide coverage for home nursing service.

This policy applies to HAP Commercial, Alliance Health and Life Insurance Company and Qualified Health Plan members age 18 years and older. Medications included in this policy that have existing medication clinical use policies must meet medication prior authorization criteria for coverage.

If you have any questions, please contact Allison White, Pharmacy Department, at (313) 664-8836.